<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/sitemap-new?view=xsl&amp;format=xsl&amp;layout=news&amp;id=2"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc><![CDATA[https://www.osservatoriomalattierare.it/malattie-rare/malattia-di-huntington/23619-malattia-di-huntington-unindagine-europea-da-voce-a-pazienti-e-famiglie]]></loc><news:news><news:publication><news:name/><news:language>it-it</news:language></news:publication><news:publication_date>2026-11-10T23:01:16Z</news:publication_date><news:title><![CDATA[Malattia di Huntington, un'indagine europea dà voce a pazienti e famiglie]]></news:title><news:keywords><![CDATA[Malattia di Huntington]]></news:keywords></news:news></url><url><loc><![CDATA[https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/23620-tumori-neuroendocrini-i-bisogni-dei-pazienti-sono-noti-servono-risposte-concrete]]></loc><news:news><news:publication><news:name/><news:language>it-it</news:language></news:publication><news:publication_date>2026-11-09T23:05:01Z</news:publication_date><news:title><![CDATA[Tumori neuroendocrini: i bisogni dei pazienti sono noti, servono risposte concrete]]></news:title><news:keywords><![CDATA[Tumori neuroendocrini]]></news:keywords></news:news></url><url><loc><![CDATA[https://www.osservatoriomalattierare.it/news/attualita/23624-tecnologie-assistive-per-ledf-ancora-troppi-gli-ostacoli-allaccesso-in-ue]]></loc><news:news><news:publication><news:name/><news:language>it-it</news:language></news:publication><news:publication_date>2026-11-10T23:01:22Z</news:publication_date><news:title><![CDATA[Tecnologie assistive, per l’EDF ancora troppi gli ostacoli all’accesso in UE]]></news:title><news:keywords><![CDATA[disabilità]]></news:keywords></news:news></url><url><loc><![CDATA[https://www.osservatoriomalattierare.it/news/attualita/23622-acalasia-esofagea-a-padova-raggiunti-i-2-000-interventi-laparoscopici-di-heller-dor]]></loc><news:news><news:publication><news:name/><news:language>it-it</news:language></news:publication><news:publication_date>2026-11-09T23:03:44Z</news:publication_date><news:title><![CDATA[Acalasia esofagea: a Padova raggiunti i 2.000 interventi laparoscopici di Heller-Dor]]></news:title><news:keywords><![CDATA[Acalasia esofagea]]></news:keywords></news:news></url><url><loc><![CDATA[https://www.osservatoriomalattierare.it/news/attualita/23621-payback-sui-dispositivi-medici-le-imprese-annunciano-ricorsi-e-proteste-contro-la-manovra]]></loc><news:news><news:publication><news:name/><news:language>it-it</news:language></news:publication><news:publication_date>2026-11-09T23:02:17Z</news:publication_date><news:title><![CDATA[Payback sui dispositivi medici, le imprese annunciano ricorsi e proteste contro la manovra]]></news:title><news:keywords><![CDATA[dispositivi medici]]></news:keywords></news:news></url><url><loc><![CDATA[https://www.osservatoriomalattierare.it/news/farmaci-orfani/23625-fibrodisplasia-ossificante-progressiva-zilurgisertib-riduce-le-formazioni-ossee-patologiche]]></loc><news:news><news:publication><news:name/><news:language>it-it</news:language></news:publication><news:publication_date>2026-11-10T23:03:49Z</news:publication_date><news:title><![CDATA[Fibrodisplasia ossificante progressiva: zilurgisertib riduce le formazioni ossee patologiche]]></news:title><news:keywords><![CDATA[Fibrodisplasia ossificante progressiva]]></news:keywords></news:news></url><url><loc><![CDATA[https://www.osservatoriomalattierare.it/news/ricerca-scientifica/23623-sindrome-di-lowe-una-nuova-strategia-terapeutica-verso-la-sperimentazione-clinica]]></loc><news:news><news:publication><news:name/><news:language>it-it</news:language></news:publication><news:publication_date>2026-11-09T16:15:09Z</news:publication_date><news:title><![CDATA[Sindrome di Lowe: una nuova strategia terapeutica verso la sperimentazione clinica]]></news:title><news:keywords><![CDATA[Sindrome di Lowe]]></news:keywords></news:news></url></urlset>